Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Esophagogastric Junction Outflow Obstruction: Current Approach to Diagnosis and Management

  • 72 Accesses


Purpose of Review

We summarize the current epidemiology, presentation, diagnostic workup, and treatment of esophagogastric junction outflow obstruction (EGJOO). We also propose a treatment algorithm based upon the literature and our personal clinical experience.

Recent Findings

EGJOO can be caused by functional obstruction (akin to achalasia), mechanical obstruction, medications, or artifact. High-resolution esophageal manometry is currently the gold standard of diagnosis. Recent research on FLIP (functional lumen imaging probe) and timed barium support use as adjunctive testing. The diagnostic yield of cross-sectional imaging is low.


Current diagnostic testing and treatment should be targeted to the suspected underlying etiology and clinical presentation of EGJOO. If functional obstruction is present with significant and persistent dysphagia, and either an abnormal FLIP or timed barium swallow, we consider therapy aimed at LES disruption (similar to achalasia). Pharmacologic therapy has a limited role. More research is needed on diagnostic and treatment modalities.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    •• Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27(2):160–74. At this time, we consider high-resolution esophageal manometry per the Chicago classification 3.0 to be the gold standard for diagnosing EGJOO.

  2. 2.

    Okeke FC, Raja S, Lynch KL, Dhalla S, Nandwani M, Stein EM, et al. What is the clinical significance of esophagogastric junction outflow obstruction? evaluation of 60 patients at a tertiary referral center. Neurogastroenterol Motil. 2017;29(6).

  3. 3.

    DeLay K, Austin GL, Menard-Katcher P. Anatomic abnormalities are common potential explanations of manometric esophagogastric junction outflow obstruction. Neurogastroenterol Motil. 2016;28(8):1166–71.

  4. 4.

    Perez-Fernandez MT, Santander C, Marinero A, Burgos-Santamaria D, Chavarria-Herbozo C. Characterization and follow-up of esophagogastric junction outflow obstruction detected by high resolution manometry. Neurogastroenterol Motil. 2016;28(1):116–26.

  5. 5.

    Triadafilopoulos G, Clarke JO. Clinical and manometric characteristics of patients with oesophagogastric outflow obstruction: towards a new classification. BMJ Open Gastroenterol. 2018;5(1):e000210.

  6. 6.

    Lynch KL, Yang YX, Metz DC, Falk GW. Clinical presentation and disease course of patients with esophagogastric junction outflow obstruction. Dis Esophagus. 2017;30(6):1–6.

  7. 7.

    Clayton SB, Patel R, Richter JE. Functional and anatomic esophagogastic junction outflow obstruction: manometry, timed barium esophagram findings, and treatment outcomes. Clin Gastroenterol Hepatol. 2016;14(6):907–11.

  8. 8.

    Triggs JR, Carlson DA, Beveridge C, Jain A, Tye MY, Kahrilas PJ, et al. Upright integrated relaxation pressure facilitates characterization of esophagogastric junction outflow obstruction. Clin Gastroenterol Hepatol. 2019.

  9. 9.

    Schupack D, Katzka DA, Geno DM, Ravi K. The clinical significance of esophagogastric junction outflow obstruction and hypercontractile esophagus in high resolution esophageal manometry. Neurogastroenterol Motil. 2017.

  10. 10.

    Jain A, Baker JR, Rubenstein JH, Chen JW. Bolus clearance in esophagogastric junction outflow obstruction is associated with strength of peristalsis. Neurogastroenterol Motil. 2017;29(9).

  11. 11.

    • Carlson DA, Kahrilas PJ, Lin Z, Hirano I, Gonsalves N, Listernick Z, et al. Evaluation of esophageal motility utilizing the functional lumen imaging probe. Am J Gastroenterol. 2016;111(12):1726–35. FLIP (functional lumen imaging probe) allows further evalution of the lower esophageal sphincter in EGJOO beyond standard high-resolution esophageal manometry, and provides additional diagnostic information. In this manuscript the Northwestern group proposes a diagnostic algorithm to approach esophageal motility disorders using FLIP.

  12. 12.

    Clayton SB, Shin CM, Ewing A, Blonski W, Richter J. Pneumatic dilation improves esophageal emptying and symptoms in patients with idiopathic esophago-gastric junction outflow obstruction. Neurogastroenterol Motil. 2019;31(3):e13522.

  13. 13.

    van Hoeij FB, Smout AJ, Bredenoord AJ. Characterization of idiopathic esophagogastric junction outflow obstruction. Neurogastroenterol Motil. 2015;27(9):1310–6.

  14. 14.

    Scherer JR, Kwiatek MA, Soper NJ, Pandolfino JE, Kahrilas PJ. Functional esophagogastric junction obstruction with intact peristalsis: a heterogeneous syndrome sometimes akin to achalasia. J Gastrointest Surg. 2009;13(12):2219–25.

  15. 15.

    Radulovic M, Schilero GJ, Yen C, Bauman WA, Wecht JM, Ivan A, et al. Greatly increased prevalence of esophageal dysmotility observed in persons with spinal cord injury. Dis Esophagus. 2015;28(7):699–704.

  16. 16.

    Ratuapli SK, Crowell MD, DiBaise JK, Vela MF, Ramirez FC, Burdick GE, et al. Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids. Am J Gastroenterol. 2015;110(7):979–84.

  17. 17.

    Dowlatshahi K, Evander A, Walther B, Skinner DB. Influence of morphine on the distal oesophagus and the lower oesophageal sphincter--a manometric study. Gut. 1985;26(8):802–6.

  18. 18.

    Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther. 2010;31(5):601–6.

  19. 19.

    Penagini R, Bartesaghi B, Zannini P, Negri G, Bianchi PA. Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia. Gut. 1993;34(1):16–20.

  20. 20.

    Penagini R, Picone A, Bianchi PA. Effect of morphine and naloxone on motor response of the human esophagus to swallowing and distension. Am J Phys. 1996;271(4 Pt 1):G675–80.

  21. 21.

    Penagini R, Bianchi PA. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology. 1997;113(2):409–14.

  22. 22.

    Shin IS, Min YW, Rhee PL. Esophagogastric junction outflow obstruction transformed to type II achalasia. J Neurogastroenterol Motil. 2016;22(2):344–5.

  23. 23.

    Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ. High-resolution manometry in clinical practice: utilizing pressure topography to classify oesophageal motility abnormalities. Neurogastroenterol Motil. 2009;21(8):796–806.

  24. 24.

    Ghosh SK, Pandolfino JE, Rice J, Clarke JO, Kwiatek M, Kahrilas PJ. Impaired deglutitive EGJ relaxation in clinical esophageal manometry: a quantitative analysis of 400 patients and 75 controls. Am J Physiol Gastrointest Liver Physiol. 2007;293(4):G878–85.

  25. 25.

    Bredenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJ, et al. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil. 2012;24(Suppl 1):57–65.

  26. 26.

    Hollenstein M, Thwaites P, Butikofer S, Heinrich H, Sauter M, Ulmer I, et al. Pharyngeal swallowing and oesophageal motility during a solid meal test: a prospective study in healthy volunteers and patients with major motility disorders. Lancet Gastroenterol Hepatol. 2017;2(9):644–53.

  27. 27.

    Regalia K, Nandwani M, Zikos T, Fernandez-Becker N, Nguyen L, Sonu I, et al. The integrated relaxation pressure may not be an appropriate gold standard for deglutitive relaxation due to the reliance on a single intragastric reference sensor in the context of significant gastric pressure heterogeneity. Digestive Disease Week, June 2-5 2018. Washington DC.

  28. 28.

    Zheng E, Gideon RM, Sloan J, Katz PO. Esophagogastric junction outflow obstruction is often associated with coexistent abnormal esophageal body motility and abnormal bolus transit. Dis Esophagus. 2017;30(10):1–4.

  29. 29.

    Beveridge CA, Falk GW, Ahuja NK, Yang YX, Metz DC, Lynch KL. Low yield of cross-sectional imaging in patients with esophagogastric junction outflow obstruction. Clin Gastroenterol Hepatol. 2019.

  30. 30.

    Hirano I, Pandolfino JE, Boeckxstaens GE. Functional lumen imaging probe for the management of esophageal disorders: expert review from the clinical practice updates committee of the AGA institute. Clin Gastroenterol Hepatol. 2017;15(3):325–34.

  31. 31.

    Rohof WO, Hirsch DP, Kessing BF, Boeckxstaens GE. Efficacy of treatment for patients with achalasia depends on the distensibility of the esophagogastric junction. Gastroenterology. 2012;143(2):328–35.

  32. 32.

    Pandolfino JE, de Ruigh A, Nicodeme F, Xiao Y, Boris L, Kahrilas PJ. Distensibility of the esophagogastric junction assessed with the functional lumen imaging probe (FLIP) in achalasia patients. Neurogastroenterol Motil. 2013;25(6):496–501.

  33. 33.

    Carlson DA, Lin Z, Kahrilas PJ, Sternbach J, Donnan EN, Friesen L, et al. The functional lumen imaging probe detects esophageal contractility not observed with manometry in patients with achalasia. Gastroenterology. 2015;149(7):1742–51.

  34. 34.

    Nassri A, Ramzan Z. Pharmacotherapy for the management of achalasia: current status, challenges and future directions. World J Gastrointest Pharmacol Ther. 2015;6(4):145–55.

  35. 35.

    Porter RF, Gyawali CP. Botulinum toxin injection in dysphagia syndromes with preserved esophageal peristalsis and incomplete lower esophageal sphincter relaxation. Neurogastroenterol Motil. 2011;23(2):139–44 e27-8.

  36. 36.

    Campos GM, Vittinghoff E, Rabl C, Takata M, Gadenstatter M, Lin F, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg. 2009;249(1):45–57.

  37. 37.

    O’Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2013;19(35):5806–12.

  38. 38.

    Hojo M, Nagahara A, Asaoka D, Takeda T, Izumi K, Matsumoto K, et al. A randomized, double-blind, pilot study of the effect of famotidine on acotiamide treatment for functional dyspepsia. Digestion. 2017;96(1):5–12.

  39. 39.

    Nakamura K, Tomita T, Oshima T, Asano H, Yamasaki T, Okugawa T, et al. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia. J Gastroenterol. 2017;52(5):602–10.

  40. 40.

    Muta K, Ihara E, Fukaura K, Tsuchida O, Ochiai T, Nakamura K. Effects of acotiamide on the esophageal motility function in patients with esophageal motility disorders: a pilot study. Digestion. 2016;94(1):9–16.

Download references

Author information

Correspondence to John O. Clarke.

Ethics declarations

Conflict of Interest

JC is a consultant for Medtronic. Thomas A. Zikos, George Triadafilopoulos, and John O. Clarke declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Esophagus

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zikos, T.A., Triadafilopoulos, G. & Clarke, J.O. Esophagogastric Junction Outflow Obstruction: Current Approach to Diagnosis and Management. Curr Gastroenterol Rep 22, 9 (2020).

Download citation


  • Esophagogastric junction outflow obstruction
  • IRP
  • Chicago classification
  • High-resolution esophageal manometry
  • Opioids
  • Functional lumen imaging probe